Hydrocortisonum Pharmaswiss (Hydrocortisone)

Hydrocortisonum Pharmaswiss is indicated for medical conditions that require systemic glucocorticoid activity. It is commonly prescribed when replacement of cortisol or suppression of inflammation is needed.

• Primary adrenal insufficiency (Addison’s disease) where endogenous cortisol production is deficient.
• Congenital adrenal hyperplasia requiring glucocorticoid replacement to control steroidogenesis.
• Acute or chronic inflammatory disorders such as rheumatoid arthritis, systemic lupus erythematosus, or severe dermatitis.
• Certain autoimmune conditions where immunosuppression helps to reduce disease activity.
• Situations of physiological stress (surgery, trauma, infection) in patients with known adrenal insufficiency.

• Hydrocortisonum Pharmaswiss delivers hydrocortisone, which acts as an agonist at intracellular glucocorticoid receptors. After oral absorption, the drug diffuses into cells, binds to the receptor complex, and translocates to the nucleus. This complex binds glucocorticoid response elements on DNA, modulating transcription of anti‑inflammatory proteins and suppressing pro‑inflammatory cytokine genes. The net effect is reduced inflammation and immune activation, as well as replacement of deficient endogenous cortisol.

Hydrocortisonum Pharmaswiss may cause a range of adverse reactions, most of which are dose‑related and reversible after discontinuation.

Common

• Mild gastrointestinal discomfort such as nausea or dyspepsia.
• Transient increase in blood glucose levels, especially in patients with diabetes.
• Fluid retention leading to mild peripheral edema.
• Mood changes including irritability or mild insomnia.
• Skin thinning or easy bruising, particularly with prolonged use.
• Increased susceptibility to minor infections such as oral thrush or urinary tract infections.

Serious

• Signs of infection that worsen rapidly, reflecting immunosuppression.
• Severe adrenal suppression causing hypotension, hyponatremia, or hypoglycemia after abrupt discontinuation.
• Osteoporosis or bone demineralization with long‑term therapy, increasing fracture risk.

Before initiating Hydrocortisonum Pharmaswiss, clinicians should evaluate patient history and monitor for conditions that could be aggravated by systemic glucocorticoids.

• Assess for active infections, as glucocorticoids can impair host defense.
• Screen for uncontrolled diabetes, hypertension, or heart failure, which may worsen with fluid retention and hyperglycemia.
• Consider bone health; patients at risk for osteoporosis should receive calcium and vitamin D supplementation.
• Avoid abrupt discontinuation; tapering is recommended to prevent adrenal crisis.
• Use caution in pregnant or breastfeeding women; benefits must outweigh potential risks.
• Monitor laboratory parameters, including blood glucose, electrolytes, and complete blood count, during therapy.

Hydrocortisonum Pharmaswiss can alter the pharmacokinetics or pharmacodynamics of several concomitant medicines; clinicians should review a patient’s medication list for potential interactions.

Avoid

• Strong CYP3A4 inducers such as rifampin, carbamazepine, or phenytoin, which may reduce hydrocortisone plasma concentrations.
• Systemic antifungal agents like ketoconazole that inhibit cortisol metabolism and may increase systemic exposure.

Use with caution

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) because combined use can increase the risk of gastrointestinal ulceration.
• Anticoagulants (e.g., warfarin) as glucocorticoids may enhance anticoagulant effects and alter INR.
• Vaccines, particularly live attenuated vaccines, since immunosuppression can diminish vaccine efficacy.
• Diabetes medications, such as insulin or oral hypoglycemics, because glucocorticoids can raise blood glucose and may require dose adjustments.